"Methods Of Isolating T Cell Receptors Having Antigenic Specificity For A Cancer-Specific Mutation" in Patent Application Approval Process (USPTO 20230203124).
In: Cancer Weekly, 2023-07-18, S. 1494
serialPeriodical
Zugriff:
The following quote was obtained by the news editors from the background information supplied by the inventors: "Adoptive cell therapy (ACT) using cells that have been genetically engineered to express an anti-cancer antigen T cell receptor (TCR) can produce positive clinical responses in some cancer patients. The method of claim 7, wherein the nucleotide sequence introduced into the autologous APCs is a tandem minigene (TMG) construct, each minigene comprising a different gene, each gene including a cancer-specific mutation that encodes a mutated amino acid sequence. [Extracted from the article]
Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Methods Of Isolating T Cell Receptors Having Antigenic Specificity For A Cancer-Specific Mutation" in Patent Application Approval Process (USPTO 20230203124).
|
---|---|
Zeitschrift: | Cancer Weekly, 2023-07-18, S. 1494 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1071-7218 (print) |
Sonstiges: |
|